Louis Garguilo

ARTICLES BY LOUIS

  • Janssen Goes From Good To Excellent Supply Chain Partners
    Janssen Goes From Good To Excellent Supply Chain Partners

    Great questions elicit enlightening answers. Especially when the first come from a wise moderator (Brendan Crowley, President, Brendan Crowley Advisors LLC), and the second a seasoned industry veteran (Remo Colarusso, Vice President, Janssen Supply Chain, Johnson & Johnson). Here’s what they had to say about drug development and manufacturing partners.

  • New U.S And Canadian Facilities Boosting Biologics Capacity
    New U.S And Canadian Facilities Boosting Biologics Capacity

    Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.

  • Pfizer’s Drivers for Manufacturing: New Tech And Regulators
    Pfizer’s Drivers for Manufacturing: New Tech And Regulators

    Regarding drug development and manufacturing – including outsourcing – Bob Betzig of Pfizer says technology has led and continues to drive change. And by the way, so do the global regulators of biopharma. 

  • Biopharma Outsourcing Will Overcome Tariff Troubles
    Biopharma Outsourcing Will Overcome Tariff Troubles

    Why has the biopharma industry insisted upon dual (or triple) sourcing for materials? Why does Big Pharma perform outsized due diligence on offshore CDMOs and CMOs? Why do we focus on costs of all materials and supply? One reason is so we can calmly weather uncertainties such as the current tariff troubles between the U.S. and China.

  • 6 Challenges For BioPharma Packaging
    6 Challenges For BioPharma Packaging

    Whether it’s innovative product-development; the need to operate globally; dealing with aging and unhealthy populations; stopping counterfeiting and theft; or facing un-harmonized serialization … biopharma packaging has its challenges.    

  • A View Of Biopharma From Pfizer’s Building 41
    A View Of Biopharma From Pfizer’s Building 41

    This is the story of a man and a building, and their tracing of decades — and hints of the future — at Pfizer, and indeed the entire biopharma industry.

  • 3 Questions To Guide You At Biopharma Conferences
    3 Questions To Guide You At Biopharma Conferences

    It’s conference season: Time for you — biopharma CEO and new employee alike — to learn and lead among others in the industry. Unfortunately, you may come up short. Here are 3 questions of existential importance to ensure that doesn’t happen at your next conferences. 

  • Large Or Small Molecule: Drug Sponsors Share API Outsourcing Philosophy
    Large Or Small Molecule: Drug Sponsors Share API Outsourcing Philosophy

    Industry Standard Research (ISR) has released two reports – one on the API outsourcing preferences and practices of small-molecule drug sponsors, and the other on those of large-molecule sponsors. I also undertook some additional analysis by comparing the reports. My driving question: Are there strategic and tactical differences for the two programs when outsourcing to CMOs? 

  • The World’s First Biopharma Built On Blockchain
    The World’s First Biopharma Built On Blockchain

    The world’s first biopharma built on blockchain technology has arrived. “We’ve created a new generation of pharmaceutical company, focused on dispersed product development through the use of today’s technology,” says Dr. Matthew Lee, Caywon Pharmaceutical Group’s VP of Innovations.

  • From CMO To CMO: A Biopharma With All The Right Moves
    From CMO To CMO: A Biopharma With All The Right Moves

    There’s a quotidian calculation to outsourcing at Allena Pharmaceuticals that's well worth studying.

    “As a small biotech, we could get kicked to the curb because somebody else has more dollars, and can occupy longer those assets at a CMO that we need. Because of this, we’ve evolved a concept of portability for our manufacturing process that may be anathema to a lot of companies …"

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.